IRIS
LARONI, ALICE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.236
AS - Asia 1.410
NA - Nord America 584
SA - Sud America 116
AF - Africa 29
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 13.377
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 11.011
SG - Singapore 607
US - Stati Uniti d'America 554
CN - Cina 382
VN - Vietnam 249
FR - Francia 99
BR - Brasile 70
HK - Hong Kong 45
DE - Germania 26
FI - Finlandia 24
AR - Argentina 23
MX - Messico 22
IQ - Iraq 18
JP - Giappone 17
GB - Regno Unito 14
IN - India 12
NL - Olanda 12
BD - Bangladesh 11
CH - Svizzera 9
ES - Italia 9
PH - Filippine 9
PK - Pakistan 9
ID - Indonesia 8
EC - Ecuador 6
KE - Kenya 6
ZA - Sudafrica 6
CL - Cile 5
AZ - Azerbaigian 4
CA - Canada 4
IE - Irlanda 4
KR - Corea 4
MA - Marocco 4
SA - Arabia Saudita 4
BO - Bolivia 3
DZ - Algeria 3
JO - Giordania 3
LT - Lituania 3
OM - Oman 3
PY - Paraguay 3
RS - Serbia 3
RU - Federazione Russa 3
TH - Thailandia 3
UA - Ucraina 3
BH - Bahrain 2
CO - Colombia 2
DO - Repubblica Dominicana 2
HR - Croazia 2
IL - Israele 2
KZ - Kazakistan 2
MY - Malesia 2
NP - Nepal 2
RO - Romania 2
SI - Slovenia 2
TN - Tunisia 2
TR - Turchia 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AO - Angola 1
AT - Austria 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BG - Bulgaria 1
CG - Congo 1
CV - Capo Verde 1
EE - Estonia 1
EG - Egitto 1
GA - Gabon 1
GF - Guiana Francese 1
HT - Haiti 1
HU - Ungheria 1
IR - Iran 1
KG - Kirghizistan 1
LB - Libano 1
LU - Lussemburgo 1
MM - Myanmar 1
MN - Mongolia 1
NI - Nicaragua 1
PE - Perù 1
PL - Polonia 1
PS - Palestinian Territory 1
PT - Portogallo 1
SE - Svezia 1
SL - Sierra Leone 1
SO - Somalia 1
SY - Repubblica araba siriana 1
TW - Taiwan 1
UZ - Uzbekistan 1
XK - ???statistics.table.value.countryCode.XK??? 1
YT - Mayotte 1
Totale 13.377
Salva come PNG Salva come JPEG
Città #
Genova 5.668
Genoa 3.513
Vado Ligure 967
Rapallo 781
Singapore 259
San Jose 244
Lauterbourg 94
Ho Chi Minh City 80
Ashburn 79
Beijing 54
Hanoi 52
Hong Kong 41
Council Bluffs 31
Frankfurt am Main 24
Helsinki 24
Bordighera 20
New York 20
Santa Clara 18
Mexico City 15
Tokyo 15
Haiphong 13
Rome 10
St Louis 10
Da Nang 8
Los Angeles 8
São Paulo 8
Biên Hòa 7
Amsterdam 6
Chicago 6
Johannesburg 6
Madrid 6
Nairobi 6
Tianjin 6
Zurich 6
Bari 5
Des Moines 5
Guangzhou 5
Karachi 5
Milan 5
Rio de Janeiro 5
Santiago 5
Baku 4
Denver 4
Dublin 4
Hải Dương 4
Karbala 4
Ninh Bình 4
Amman 3
Baghdad 3
Belgrade 3
Can Tho 3
Cardiff 3
Changsha 3
Chennai 3
Hangzhou 3
Orem 3
Paris 3
Quảng Ngãi 3
Sorocaba 3
Thái Bình 3
Thái Nguyên 3
Vĩnh Long 3
Vũng Tàu 3
Almaty 2
Asunción 2
Bologna 2
Buffalo 2
Caracas 2
Chongqing 2
City of London 2
Contagem 2
Cuenca 2
Curitiba 2
Jakarta 2
Kyiv 2
Ljubljana 2
London 2
Manila 2
Miami 2
Montreal 2
Naga 2
Nola 2
Oberengstringen 2
Porto Alegre 2
Quezon City 2
Quilmes 2
Quito 2
Quận Ba 2
Riyadh 2
San Luis 2
Santa Cruz de la Sierra 2
Shanghai 2
Shenzhen 2
Sulaymaniyah 2
Tel Aviv 2
Thanh Hóa 2
Todi 2
Toronto 2
Vĩnh Tường 2
Zagreb 2
Totale 12.286
Salva come PNG Salva come JPEG
Nome #
Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MS 259
Finger motor performance as a new quantitative clinical endpoint in multiple sclerosis 238
Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy 236
Neuroprotective features of mesenchymal stem cells. 214
Dysregulation of regulatory CD56bright NK cells/T cells interactions in multiple sclerosis 213
Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. 212
Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption 203
In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma 197
Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification. 193
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. 180
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved? 177
Teriflunomide treatment reduces B cells in patients with MS. 171
Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. 170
A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study 168
A case of thyroiditis during natalizumab therapy for multiple sclerosis 167
Hypothalamic AgRP neurons control hematopoiesis and lymphopoiesis and are activated in experimental MS 166
Three years of experience: the Italian registry and safety data update 166
Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod 161
Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study 158
T-cell trafficking in the central nervous system. 158
Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases 157
Clinical baseline factors predict response to natalizumab: their usefulness in patient selection. 155
Approved drugs for multiple sclerosis: The challenge of choice 155
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis 154
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. 152
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study 151
Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group 149
Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation 147
JCV-DNA testing during natalizumab treatment is complementary to anti-JCV antibodies for PML risk stratification 146
Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report 146
Mesenchymal stem cells as treatment for MS - progress to date. 143
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis 143
Role of the innate immune system in the pathogenesis of multiple sclerosis. 140
Unraveling the regulatory role of NK cells on T-cell effector functions: Implications for CNS autoimmunity 138
To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy 138
Can we kill an extra bird with the same stone? 137
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. 135
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy 135
Wernicke's syndrome during parenteral feeding: not an unusual complication. 134
Do NK cells play a role in the possible association between natalizumab treatment and the development of melanoma? 132
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome 132
Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution 132
Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab 132
Regulatory Functions of Natural Killer Cells in Multiple Sclerosis 131
MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis 125
IL-27 imparts immunoregulatory function to human NK cell subsets. 124
Impact of treatment on cellular immunophenotype in MS: A cross-sectional study 123
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 123
The early effect of cladribrine versus fingolimod on clinical and MRI measures in relapsing remitting multiple sclerosis 120
Assessing upper limb function in Multiple Sclerosis by an engineered glove 120
A pilot study comparing myelin measurements from [18F]-Florbetaben PET and quantitative T1 map imaging in multiple sclerosis (MS) 119
The short-chain fatty acid butyrate decreases the regulatory function of human natural killer cells and promotes their maturation 119
Long-term disability progression in primary progressive multiple sclerosis: A 15-year study 117
Dysregulation of regulatory CD56 (bright) NK cells/T cells interactions in multiple sclerosis 116
Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy 116
Epstein-Barr-negative MS: a true phenomenon? 114
The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL 114
Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study 114
Natural killer cells are functionally defective in multiple sclerosis 112
Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study 112
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks 111
Multiple sclerosis and autoimmune diseases: epidemiology and HLA-DR association in North-east Italy. 111
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies 111
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study 109
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks 107
Towards clinical application of mesenchymal stem cells for treatment of neurological diseases of the central nervous system. 106
Health-related quality of life in multiple sclerosis: Effects of natalizumab 105
Impaired suppressor function of NK cells in multiple sclerosis 104
CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis 103
Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey 102
Interferon beta potentiates the therapeutic activity of mesenchymal stem cells 99
Enhancing natural killer cells is beneficial in multiple sclerosis - Yes 99
Aging with multiple sclerosis: Clinical characterization of an elderly population, a cross-sectional study 98
Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis 95
Impaired suppressor function of CD56bright NK cells in early multiple sclerosis 94
Tailoring B cell depletion therapy in MS according to memory B cell monitoring 92
Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: who gains from it? 91
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study 90
Effect of ocrelizumab treatment on retinal atrophy: preliminary results from a single-center observational study 89
COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments 89
Beyond steady-state amyloid PET to detect demyelination in multiple sclerosis (MS) 89
A real-world study of alemtuzumab in a cohort of Italian patients 88
Multivariate clinically isolated syndrome (CIS) risk factor study: towards individual prognosis and treatment indication in CIS 87
Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic? 86
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies 86
The effect of Cladribine and Fingolimod treatments on retinal atrophy 85
MESEMS: a randomized, double blind placebo-controlled cross-over study to evaluate safety and efficacy of intravenous administration of autologous mesenchymal stem cells in patients with multiple sclerosis 85
CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis 85
Mesenchymal stem cells for multiple sclerosis: effect of treatment on peripheral immune cells 81
Mesenchymal stem cells for the treatment of neurological diseases: Immunoregulation beyond neuroprotection 81
Immune Soluble Factors in the Cerebrospinal Fluid of Progressive Multiple Sclerosis Patients Segregate Into Two Groups 79
Nonfunctional natural killer regulatory cells in multiple sclerosis 78
Effect of SARS-CoV-2 vaccination on natural killer cell responses in multiple sclerosis 76
Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient Perspectives 72
Family Functioning and Multiple Sclerosis: preliminary data of a Multicentric Italian Project 67
Cladribine Tablets Mode of Action, Learning from the Pandemic: A Narrative Review 67
To switch therapies in RRMS: why and when? A real-life multicentre study. 67
Mesenchymal Stem/Stromal Cells for Multiple Sclerosis and Other Neurological Diseases 65
Cladribine vs other drugs in MS: Merging randomized trial with real-life data 64
Ageing with MS: a cross sectional study 63
Totale 12.665
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.594
article - articoli 45.809
book - libri 0
conference - conferenze 451
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 334
Totale 93.188
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021257 0 0 0 0 0 0 0 0 0 110 75 72
2021/20221.094 45 28 84 111 44 94 40 252 74 113 66 143
2022/2023960 99 74 15 78 149 163 6 67 171 15 102 21
2023/2024765 41 84 9 88 66 84 53 70 69 18 46 137
2024/20252.508 104 214 96 158 294 293 262 421 121 138 183 224
2025/20263.585 510 114 244 388 538 343 592 247 268 341 0 0
Totale 13.749